Common use of EXPERTS Clause in Contracts

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tocagen. The address of the SEC website is xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectus.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 20172022, as set forth in their reportreport (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE ADDITIONAL INFORMATION This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus or dealer has incorporated by reference. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website xxxxx.xxx.xxx that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SECregistrants. Our SEC filings, including Tocagen. The address of our registration statement and the exhibits and schedules thereto, are available on the SEC website is at xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectus.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our The consolidated financial statements included incorporated in our this prospectus supplement by reference from the Company’s Annual Report on Form 10-K for the year ended December 31, 20172019 and the effectiveness of our internal control over financial reporting as of December 31, 2019 have been audited by CohnReznick LLP, an independent registered public accounting firm, as set forth in their reportreports thereon, which is included therein, and incorporated herein by reference in this prospectus and elsewhere in the registration statementreference. Our Such consolidated financial statements are incorporated herein by reference in reliance on Ernst & Young LLP’s report, upon such reports given on their the authority of such firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of We have filed a registration statement we filed on Form S-3 with the SECSEC for the shares of common stock offered by this prospectus supplement and the accompanying prospectus. This prospectus does supplement and the accompanying prospectus, including the information incorporated by reference herein and therein, do not contain include all of the information set forth contained in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we You should refer you to the registration statement and the its exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different for additional information. We file annual, quarterly and periodic reports, proxy statements and other information with the SEC. Many of our SEC filings are not making an offer of these securities in any state where available to the offer is not permitted. You should not assume that public from the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectusSEC’s website: xxx.xxx.xxx. We file make available free of charge our annual, quarterly and current reports, proxy statements and other information with upon request. To request such materials, please contact us at the SECfollowing address or telephone number: ADMA Biologics, Inc. 000 Xxxxx 00, Xxxxxx, Xxx Xxxxxx 00000, Attention: Xxxxx Xxxx, Executive Vice President and Chief Financial Officer, (000) 000-0000 .. Exhibits to the documents will not be sent, unless those exhibits have specifically been incorporated by reference in this prospectus. You may read and copy the registration statementalso obtain reports, as well as any statements or other document filed by us information that we file with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents SEC by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tocagen. The address of the SEC website is xxx.xxx.xxx. We maintain a accessing our website at xxx.xxxxxxx.xxxxxx.xxxxxxxxxxxxx.xxx, under the Investors tab, SEC Filings. Information contained in in, or accessible through through, our website does not constitute a part of this prospectusprospectus or any accompanying prospectus supplement.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 20172022, as set forth in their reportreport (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus supplement and the accompanying prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of We have filed a registration statement we filed on Form S-3 with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and SEC for the securities we are offering under by this prospectus, we prospectus supplement. This prospectus supplement does not include all of the information contained in the registration statement. You should refer you to the registration statement and the its exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different for additional information. We are not making an offer will provide to each person, including any beneficial owner, to whom a prospectus supplement is delivered, a copy of these securities in any state where the offer is not permitted. You should not assume that or all of the information that has been incorporated by reference in this the prospectus is accurate as of any date other than supplement but not delivered with the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectussupplement. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website xxxxx.xxx.xxx that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SECregistrants. Our SEC filings, including Tocagen. The address of our registration statement and the exhibits and schedules thereto, are available on the SEC website is at xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectus.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our The financial statements included incorporated in our this prospectus by reference from the Company’s Annual Report on Form 10-K for the year ended December 31have been audited by Deloitte & Touche LLP, 2017an independent registered public accounting firm, as set forth stated in their report, which is incorporated herein by reference in this prospectus and elsewhere in the registration statementreference. Our Such financial statements are have been so incorporated by reference in reliance on Ernst & Young LLP’s report, upon the report of such firm given on upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus or dealer has incorporated by reference into this prospectus. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including TocagenFulgent. The address of the SEC website is xxx.xxx.xxxw xx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxxw xx.xxxxxxxxxxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectus.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 20172020, as set forth in their reportreport (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. INFORMATION; INCORPORATION BY REFERENCE Available Information We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that about issuers, such as us, who file electronically with the SEC, including Tocagen. The address of the SEC that website is xxx.xxx.xxx. We maintain a Our website at address is xxx.xxxxxxx.xxx. Information contained in or accessible through The information on our website does website, however, is not, and shall not constitute be deemed to be, a part of this prospectusprospectus supplement. This prospectus supplement and the accompanying base prospectus are part of a registration statement that we filed with the SEC, and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement. Statements in this prospectus supplement or the accompanying base prospectus about these documents are summaries, and each such statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 20172020, as set forth in their reportreport (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus is supplement and the accompanying prospectus are part of a the registration statement on Form S-3 we filed with the SEC. This prospectus does SEC under the Securities Act and do not contain all of the information set forth in the registration statement statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits to the registration statement. For further information with respect to us and the securities we that are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter statement or dealer has authorized any person the exhibits to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information reports or other documents incorporated by reference in this prospectus is accurate as supplement and the accompanying prospectus for a copy of any date such contract, agreement or other than document. Because we are subject to the date on the front page of this prospectus, regardless information and reporting requirements of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement, as well as any other document filed by us with public over the SEC, Internet at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tocagen. The address of the SEC website is xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectusxxxx://xxx.xxx.xxx.

EXPERTS. ‌ Ernst & Young The consolidated financial statements of Zynerba Pharmaceuticals, Inc. and subsidiary as of December 31, 2020 and 2019 and for each of the years in the three-year period ended December 31, 2020, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, as set forth in their report, which is incorporated by reference in this prospectus herein, and elsewhere in upon the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority of said firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectusprospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus supplement or dealer has incorporated by reference. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectusprospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectusprospectus supplement. We are currently subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and in accordance therewith file annual, quarterly and current periodic reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed by us with the SEC, at Our SEC filings are available to you on the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tocagen. The address of the SEC website is xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained xxxx://xxx.xxx.xxx and in or accessible through the “Investor Relations” section of our website does at xxxx://xxx.xxxxxxx.xxx. Our website and the information contained on that site, or connected to that site, are not constitute incorporated into and are not a part of this prospectusprospectus supplement.

EXPERTS. ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our The consolidated financial statements included of NuZee, Inc. as of September 30, 2021 and 2020 and for each of the two years in our the period ended September 30, 2021, incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended December 31September 30, 2017, as set forth in their report, which is 2021 have been so incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst & Young the report of MaloneBailey, LLP’s report, an independent registered public accounting firm, given on their the authority of said firm as experts in accounting auditing and auditingaccounting. WHERE YOU WHEREYOU CAN FIND MORE INFORMATION This prospectus is part of MOREINFORMATION We have filed with the SEC a registration statement we filed on Form S-3 under the Securities Act with respect to the SECcommon stock offered by this prospectus supplement and the accompanying prospectus. This prospectus does supplement and the accompanying prospectus are part of that registration statement, but do not contain all of the information set forth included in the registration statement and or the exhibits to the registration statementexhibits. For further information with respect to us and the securities we are offering under this prospectusabout us, we refer you to the registration statement and the to its exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permittedschedules. You should not assume that may obtain the information in this prospectus is accurate full registration statement and exhibits from the SEC or from us, as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectusprovided below. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available over the registration statement, as well as any other document filed by us with the SEC, Internet at the SEC’s Public Reference Room website at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330xxx.xxx.xxx. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including TocagenSEC at xxxx://xxx.xxx.xxx. Our website address is xxx.xxxxxxx.xxx. The address of the SEC information contained on, or that can be accessed through, our website is xxx.xxx.xxx. We maintain a website at xxx.xxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of this prospectus supplement or the accompanying prospectus or incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider information on our website to be part of this prospectus supplement or the accompanying prospectus. We have included our website address as an inactive textual reference only.